MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2026.101463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Wang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Hauptthemen laut MEDLINE: Kruppel-Like Transcription Factors, Glyceraldehyde-3-Phosphate Dehydrogenases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Drug resistance to the androgen receptor (AR) antagonist is a critical obstacle in the clinic for advanced prostate cancers. Especially, AR antagonist treatment-induced neuroendocrine progression represents a lethal and therapy-resistant subtype. Although transcriptional and epigenetic lineage plasticity have been extensively implicated in treatment-induced neuroendocrine progression, the contribution of metabolic adaptation remains incompletely understood. Here, we identified a previously unrecognized metabolic reprogramming mechanism induced by AR antagonists in castration-resistant prostate cancer (CRPC) models. AR antagonist treatment markedly enhanced glycolytic activity and induced glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Genetic depletion of GAPDH suppressed AR antagonist-induced glycolytic activation, altered transcriptomic and metabolic programs, reduced neuroendocrine-associated marker expression, and inhibited xenograft tumor growth. Mechanistically, GAPDH promoter pulldown coupled with mass spectrometry, siRNA screening, and chromatin immunoprecipitation assays identified myeloid zinc finger-1 (MZF1) as a key transcription factor for Enzalutamide-induced GAPDH gene expression. Pharmacological inhibition of GAPDH using koningic acid (KA) or penta-O-galloyl-β-D-glucopyranose (PGG) significantly suppressed tumor growth and attenuated neuroendocrine-associated molecular programs in CRPC cell-derived xenograft and patient-derived t-NEPC xenograft models. Collectively, our findings identify an AR antagonist-induced MZF1-GAPDH signaling axis that promotes glycolytic activation and neuroendocrine-associated metabolic adaptation during treatment resistance. These results support targeting GAPDH-dependent metabolic reprogramming as a potential therapeutic strategy for treatment-resistant prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Departments of Pathology & Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Electrical Engineering & Computer Science, The University of Kansas School of Engineering, Lawrence, KS 66045, USA.
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada.
- Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA; Departments of Pathology & Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Electroni…
Zitieren
APA
Liu, W., He, L., Zhong, C., Wang, Y., Zhang, D., Mirza, M., & Li, B. (2026). MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101463
Vancouver
Liu W, He L, Zhong C, Wang Y, Zhang D, Mirza M, et al. MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101463
BibTeX
@article{Liu2026,
author = {Liu, Wang and He, Lily and Zhong, Cuncong and Wang, Yuzhuo and Zhang, Da and Mirza, Moben and Li, Benyi},
title = {MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2026.101463}
}
EUVIMED